These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24949489)

  • 1. Approaches to modelling the human immune response in transition of candidates from research to development.
    Williamson D
    J Immunol Res; 2014; 2014():395302. PubMed ID: 24949489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization for bacterial respiratory infections.
    Cripps AW
    Hum Vaccin; 2008; 4(6):396-9. PubMed ID: 18838872
    [No Abstract]   [Full Text] [Related]  

  • 3. A Combination of Polybacterial MV140 and
    Martin-Cruz L; Sevilla-Ortega C; Benito-Villalvilla C; Diez-Rivero CM; Sanchez-Ramón S; Subiza JL; Palomares O
    Front Immunol; 2020; 11():612269. PubMed ID: 33552074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Polyvalent Vaccine Candidates From Extracellular Secretory Proteins in
    Peng YM; Tao JJ; Kuang SF; Jiang M; Peng XX; Li H
    Front Immunol; 2021; 12():736360. PubMed ID: 34671354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization against respiratory bacterial pathogens.
    Foxwell AR; Kyd JM; Cripps AW
    Expert Rev Vaccines; 2003 Aug; 2(4):551-60. PubMed ID: 14711339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral administration of "Infectvac" for prevention of acute respiratory tract infections].
    Luther P; Brachmann I; Werchan D; Wittig C; Tischner H
    Z Erkr Atmungsorgane; 1990; 175(2):95-9. PubMed ID: 2264367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal vaccines for protection against respiratory and systemic bacterial infections.
    Oliveira ML; Arêas AP; Ho PL
    Expert Rev Vaccines; 2007 Jun; 6(3):419-29. PubMed ID: 17542756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects.
    Sánchez-Ramón S; Pérez de Diego R; Dieli-Crimi R; Subiza JL
    Curr Drug Targets; 2014; 15(12):1132-43. PubMed ID: 25330031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based.
    Cai W; Kesavan DK; Wan J; Abdelaziz MH; Su Z; Xu H
    Diagn Pathol; 2018 Dec; 13(1):95. PubMed ID: 30537996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines: a review.
    Lewis PJ; Babiuk LA
    Adv Virus Res; 1999; 54():129-88. PubMed ID: 10547676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of infections of the respiratory tract using the oral application of antigens.
    Tischner H
    Z Erkr Atmungsorgane; 1991; 176(2-3):131-7. PubMed ID: 1858413
    [No Abstract]   [Full Text] [Related]  

  • 12. [Status and prospects of immunologic disease prevention].
    Morunova AA
    Pediatriia; 1989; (7):5-7. PubMed ID: 2780160
    [No Abstract]   [Full Text] [Related]  

  • 13. Immuno-modulatory role of porins: host immune responses, signaling mechanisms and vaccine potential.
    Sakharwade SC; Prasad GV; Mukhopadhaya A
    Adv Exp Med Biol; 2015; 842():79-108. PubMed ID: 25408338
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacterial polysaccharides: conformation, dynamics and molecular recognition by antibodies.
    Gómez-Redondo M; Ardá A; Gimeno A; Jiménez-Barbero J
    Drug Discov Today Technol; 2020 Dec; 35-36():1-11. PubMed ID: 33388123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of immunology to the rational design of novel antibacterial vaccines.
    Kaufmann SH
    Nat Rev Microbiol; 2007 Jul; 5(7):491-504. PubMed ID: 17558425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Vaccines & Immunotherapeutics: News.
    Hum Vaccin Immunother; 2015; 11(10):2334-6. PubMed ID: 26376013
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen.
    Salehen N; Stover C
    Vaccine; 2008 Jan; 26(4):451-9. PubMed ID: 18162264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized vaccination? II. The role of natural microbiota in a vaccine-induced immunity.
    Długońska H; Grzybowski M
    Wiad Parazytol; 2011; 57(2):71-6. PubMed ID: 21682089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-β-(1→6)-N-acetyl-d-glucosamine exopolysaccharide.
    Gening ML; Pier GB; Nifantiev NE
    Drug Discov Today Technol; 2020 Dec; 35-36():13-21. PubMed ID: 33388124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.
    Dennehy R; McClean S
    Curr Protein Pept Sci; 2012 Dec; 13(8):807-15. PubMed ID: 23305366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.